Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) antibody

Catalog No. ABIN7795083

The Humanized Monoclonal anti-ErbB2/Her2 (Trastuzumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect ErbB2/Her2 (Trastuzumab Biosimilar) in samples from Human.

Quick Overview for Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) antibody (ABIN7795083)

Target: ErbB2/Her2 (Trastuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This ErbB2/Her2 (Trastuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-ErbB2/Her2 (Trastuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Trastuzumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant

Characteristics: Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions, when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: A431 cells overexpressing human EGFR

Isotype: L234A, L235A, P329G

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for ErbB2/Her2 (Trastuzumab Biosimilar)

Target: ErbB2/Her2 (Trastuzumab Biosimilar)

Alternative Name: Trastuzumab Biosimilar

Target Type: Biosimilar